ADVERTISEMENT
ADVERTISEMENT
macrophage, cancer biology, CAR, chimeric antigen receptor, CAR T cells, solid cancer, tumor, liquid cancer, immunotherapy, immunology, disease & medicine, techniques
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

solid cancer
A wrecking ball destroying a malignant cell as a 3D illustration
Armored CAR T Cells Break Through Immune Suppression in Solid Tumors
Jennifer Zieba, PhD | Sep 26, 2022 | 3 min read
Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.
Finding CAR T Cells in Solid Tumors by Single-Cell Resolution
Finding CAR T Cells in Solid Tumors at Single-Cell Resolution
The Scientist Creative Services Team in collaboration with Miltenyi Biotec | Nov 12, 2021 | 1 min read
Rita Pfeifer will discuss visualizing and quantifying CAR T-cell infiltration into solid tumors with 3-D light sheet fluorescence microscopy (LSFM).
Discover How to Accelerate and Improve CAR-T therapy development
Advances in Solid Tumor Immunotherapies
Sartorius | Oct 6, 2021 | 1 min read
By screening for novel tumor targets, researchers build better CAR-T cell therapies.
Enhancing the Efficacy of CAR-T Cell Therapies
The Scientist Creative Services Team in Collaboration with IsoPlexis | Jun 29, 2021 | 1 min read
Jessica Morris will discuss strategies to improve CAR-T cell targeting, activation, and killing capabilities.
cancer blood hematologic leukemia solid tumor covid-19 sars-cov-2 coronavirus pandemic mortality t cell b cd8+ cd4+ immunology chemotherapy
COVID-19 More Deadly with Blood than Solid Cancer: Study
Marcus A. Banks | Feb 16, 2021 | 4 min read
Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.
CAR T cells, oncolytic virus, CD19, mouse model, solid cancer, liquid cancer, tumor, immune response, immunotherapy, T cell, treatment
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020 | 5 min read
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
ADVERTISEMENT